Intellia Therapeutics Inc (NASDAQ:NTLA) was up 10.4% during trading on Friday . The company traded as high as $19.75 and last traded at $19.50, with a volume of 340,649 shares changing hands. The stock had previously closed at $17.66.

A number of equities research analysts have recently commented on NTLA shares. Jefferies Group started coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They set a “hold” rating and a $33.00 price objective for the company. Credit Suisse Group AG started coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They set an “outperform” rating and a $39.00 price objective for the company. Wedbush started coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They set an “outperform” rating and a $38.00 price objective for the company. Leerink Swann started coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They set a “market perform” rating and a $32.00 price objective for the company. Finally, Zacks Investment Research downgraded Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $35.50.

The stock’s 50 day moving average price is $20.81 and its 200-day moving average price is $23.58. The firm’s market capitalization is $726.76 million.

In other news, major shareholder Institutes For Biomed Novartis acquired 277,777 shares of the company’s stock in a transaction dated Wednesday, May 11th. The stock was bought at an average price of $18.00 per share, with a total value of $4,999,986.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Bros. Advisors Lp Baker acquired 200,000 shares of the company’s stock in a transaction dated Wednesday, May 11th. The shares were purchased at an average cost of $18.00 per share, with a total value of $3,600,000.00. The disclosure for this purchase can be found here.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.